## Answer
(model generated chain of thought explanation)

Given the patient's presentation, which includes a history of depression and recent switch to fluoxetine (a selective serotonin reuptake inhibitor or SSRI), it is essential to consider the potential side effects of SSRIs, such as extrapyramidal symptoms (EPS). EPS can include dystonia, parkinsonism, akathisia, and tardive dyskinesia.

The patient's current presentation of mutism, resistance to movement, and inability to respond to external stimuli despite attempts to engage her in conversation or physical contact is highly suggestive of a side effect of fluoxetine. The fact that she remains mute and ignores external stimuli further supports this diagnosis.

Considering the potential for EPS as a side effect of SSRIs, the best initial therapy would be to address these symptoms directly. Among the options provided:

A. Benztropine - This is an anticholinergic medication commonly used to treat EPS. It can help alleviate symptoms such as dystonia and parkinsonism.

B. Electroconvulsive therapy (ECT) - While ECT may be considered in severe cases of depression, it is not typically the first-line treatment for a patient with a history of SSRIs and current presentation of mutism.

C. Haloperidol - This is an antipsychotic medication that can also be used to treat EPS. However, its use would depend on the severity of the symptoms and the presence of other psychiatric conditions.

D. Lorazepam - This is a benzodiazepine that may provide temporary relief from anxiety or agitation but does not address the underlying cause of mutism in this context.

Given the patient's presentation and history, addressing EPS directly with an anticholinergic medication like benztropine would be the most appropriate initial therapy to alleviate her symptoms. This approach is less likely to exacerbate EPS compared to other options listed.

Therefore, the best initial therapy for this patient would be A. Benztropine.